Poll: docs say don't take away CME support

Share this article:
A poll of 268 physicians found that 92% disagree with an American Medical Association (AMA) committee's call to end commercial support of CME.

Respondents to the online poll, by med ed provider Pri-Med, expressed concern that a ban on commercial support would make it more expensive for them to receive CME and that the quality of CME would decrease, making it harder for physicians to stay up to date and ultimately impacting patient care.
“I don't receive CME reimbursement from my employer,” said one respondent. “Any subsidy is very beneficial to me.”

Last month, the AMA's Council on Ethical and Judicial Affairs, which makes ethics policy for the society, issued a report arguing that physicians and institutions of medicine should not accept commercial support for CME except for narrow technical training on new diagnostic or therapeutic devices and techniques. The report's recommendations will be taken up by the AMA House of Delegates at its annual meeting, June 14-18 in Chicago.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...